Literature DB >> 6126068

Naloxone-induced reduction of schizophrenic symptoms.

H A Jørgensen, C Cappelen.   

Abstract

A schizophrenic patient was repeatedly treated with intravenous naloxone 0.04 mg or saline in a double-blind design. The Comprehensive Psychopathological Rating Scale was used to quantify the symptoms before and after each injection. Naloxone significantly reduced the symptoms temporarily, whereas saline was without effect.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6126068     DOI： 10.1111/j.1600-0447.1982.tb00858.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN： 0001-690X            Impact factor:   6.392


  4 in total

Review 1.  Naloxone: new therapeutic roles.

Authors:  B Milne; K Jhamandas
Journal:  Can Anaesth Soc J       Date:  1984-05

Review 2.  Peptide neuroregulators: the opioid system as a model.

Authors:  J D Barchas; C Evans; G R Elliott; P A Berger
Journal:  Yale J Biol Med       Date:  1985 Nov-Dec

Review 3.  Bread and Other Edible Agents of Mental Disease.

Authors:  Paola Bressan; Peter Kramer
Journal:  Front Hum Neurosci       Date:  2016-03-29       Impact factor: 3.169

4.  Opioid antagonists are associated with a reduction in the symptoms of schizophrenia: a meta-analysis of controlled trials.

Authors:  Samuel D Clark; Jared X Van Snellenberg; Jacqueline M Lawson; Anissa Abi-Dargham
Journal:  Neuropsychopharmacology       Date:  2020-06-09       Impact factor: 7.853
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.